Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 50:119-127, doi:10.1016/j.jacc.2007.04.031 (Published online 21 May 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2007.04.031v1
50/2/119    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaffe, R.
Right arrow Articles by Strauss, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaffe, R.
Right arrow Articles by Strauss, B. H.

FOCUS ISSUE: DRUG-ELUTING STENTS: STATE-OF-THE-ART PAPER

Late and Very Late Thrombosis of Drug-Eluting Stents

Evolving Concepts and Perspectives

Ronen Jaffe, MD and Bradley H. Strauss, MD, PhD, FACC*

Schulich Heart Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

Manuscript received February 12, 2007; revised manuscript received March 30, 2007, accepted April 2, 2007.

* Reprint requests and correspondence: Dr. Bradley H. Strauss, Reichmann Research Chair in Cardiovascular Sciences, Sunnybrook Health Sciences Center, 2075 Bayview Avenue, Suite A-253, Toronto, Ontario, Canada M4N 3M5 (Email: bradley.strauss{at}sunnybrook.ca).

Coronary stents are the mainstay of percutaneous coronary revascularization procedures and have significantly decreased the rates of acute vessel closure and restenosis. Stent thrombosis (ST) after percutaneous coronary intervention is an uncommon and potentially catastrophic event that might manifest as myocardial infarction and sudden death. Optimization of stent implantation and dual antiplatelet therapy have markedly reduced the occurrence of this complication. Bare-metal stent (BMS) thrombosis occurs in <1% of the cases, usually within the first month after implantation. The advent of drug-eluting stents (DES) has raised concerns regarding later occurrence of ST, beyond the traditional 1-month timeframe, especially in complex lesion subsets that were excluded from randomized trials that compared BMS to DES. There is widespread controversy regarding the actual incremental risk associated with DES. Recent studies suggest a 0.5% increased long-term thrombosis risk with DES; however, the clinical significance of these events remains under debate. The degree of protection achieved by dual antiplatelet therapy and optimal duration of treatment are under investigation. Novel stent designs might potentially decrease the incidence of this event. In this review, we will describe the current knowledge of the pathophysiology of late DES thrombosis, although many aspects remain incompletely understood.

Abbreviations and Acronyms
  BMS = bare-metal stent(s)
  DES = drug-eluting stent(s)
  MI = myocardial infarction
  PCI = percutaneous coronary intervention
  PES = paclitaxel-eluting stent(s)
  SES = sirolimus-eluting stent(s)
  ST = stent thrombosis




This article has been cited by other articles:


Home page
Circ Cardiovasc IntervHome page
T. Palmerini, G. Dangas, R. Mehran, A. Caixeta, P. Genereux, M. P. Fahy, K. Xu, E. Cristea, A. J. Lansky, and G. W. Stone
Predictors and Implications of Stent Thrombosis in Non-ST-Segment Elevation Acute Coronary Syndromes: The ACUITY Trial
Circ Cardiovasc Interv, December 1, 2011; 4(6): 577 - 584.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
T. Inoue, K. Croce, T. Morooka, M. Sakuma, K. Node, and D. I. Simon
Vascular Inflammation and Repair: Implications for Re-Endothelialization, Restenosis, and Stent Thrombosis
J. Am. Coll. Cardiol. Intv., October 1, 2011; 4(10): 1057 - 1066.
[Abstract] [Full Text] [PDF]


Home page
Cardiac Cath Lab DirectorHome page
A. Yehya and M. K. Mandawat
Intravascular Ultrasound: Its Use and Limitations in Cardiac Catheterization Laboratory
Cardiac Cath Lab Director, April 1, 2011; 1(2): 67 - 71.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
T.-H. Chen and R. Matyal
The Management of Antiplatelet Therapy in Patients With Coronary Stents Undergoing Noncardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2010; 14(4): 256 - 273.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
G. Niccoli, R. A. Montone, G. Ferrante, and F. Crea
The Evolving Role of Inflammatory Biomarkers in Risk Assessment After Stent Implantation
J. Am. Coll. Cardiol., November 23, 2010; 56(22): 1783 - 1793.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
J. M. de la Torre Hernandez, F. Alfonso, F. Gimeno, J. A. Diarte, R. Lopez-Palop, A. Perez de Prado, F. Rivero, J. Sanchis, M. Larman, J. F. Diaz, et al.
Thrombosis of Second-Generation Drug-Eluting Stents in Real Practice: Results From the Multicenter Spanish Registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2)
J. Am. Coll. Cardiol. Intv., September 1, 2010; 3(9): 911 - 919.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc IntervHome page
N. L. M. Cruden, S. A. Harding, A. D. Flapan, C. Graham, S. H. Wild, R. Slack, J. P. Pell, D. E. Newby, and on behalf of the Scottish Coronary Revascularisati
Previous Coronary Stent Implantation and Cardiac Events in Patients Undergoing Noncardiac Surgery
Circ Cardiovasc Interv, June 1, 2010; 3(3): 236 - 242.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Liistro, M. Fineschi, S. Grotti, P. Angioli, A. Carrera, K. Ducci, T. Gori, G. Falsini, C. Pierli, and L. Bolognese
Long-Term Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis: Results of the TRUE (Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis) Registry at 4 Years
J. Am. Coll. Cardiol., February 16, 2010; 55(7): 613 - 616.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc IntervHome page
J. M. Lasala, D. A. Cox, D. Dobies, K. Baran, W. B. Bachinsky, E. W. Rogers, J. A. Breall, D. H. Lewis, A. Song, R. M. Starzyk, et al.
Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries
Circ Cardiovasc Interv, August 1, 2009; 2(4): 285 - 293.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
H. Samady, M. McDaniel, E. Veledar, B. De Bruyne, N. H. Pijls, W. F. Fearon, and V. Vaccarino
Baseline Fractional Flow Reserve and Stent Diameter Predict Optimal Post-Stent Fractional Flow Reserve and Major Adverse Cardiac Events After Bare-Metal Stent Deployment
J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 357 - 363.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. J. Eisenberg, P. R. Richard, D. Libersan, and K. B. Filion
Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents
Circulation, March 31, 2009; 119(12): 1634 - 1642.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. Burzotta, A. Parma, C. Pristipino, A. Manzoli, F. Belloni, G. Sardella, S. Rigattieri, A. Danesi, P. Mazzarotto, F. Summaria, et al.
Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study
Eur. Heart J., December 2, 2008; 29(24): 3011 - 3021.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
L. T. Newsome, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Anesth. Analg., August 1, 2008; 107(2): 552 - 569.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Meliga, H. M. Garcia-Garcia, M. Valgimigli, A. Chieffo, G. Biondi-Zoccai, A. O. Maree, S. Cook, L. Reardon, C. Moretti, S. De Servi, et al.
Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease: The DELFT (Drug Eluting stent for LeFT main) Registry
J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2212 - 2219.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon
Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 137 - 146.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement